Agreed jthunder, management doing an excellent job promoting the company in the US. From the article you posted:
"The tumor antigen being targeted by Prima is called mucin-1, a molecule expressed by a variety of tumors including breast, ovarian, prostate, lung and colon cancers"
Dendreons Provenge is used to treat prostate cancer. Prima have stated that they intend using their product to target all the cancers expressing the mucin-1 molecule...INCLUDING PROSTATE CANCER.
Does anyone see the situation where a multi billion dollar company in Dendreon would let a little Aussie company come in and steal their thunder??? Or would it be more likely for Dendreon to swallow up Prima Biomed, with all its intellectual property and patents, so as to protect their market???
Interesting times ahead...
PRR Price at posting:
29.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)